Aerius syrup

Ülke: Ermenistan

Dil: İngilizce

Kaynak: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktif bileşen:

desloratadine

Mevcut itibaren:

Schering-Plough Labo N.V.

ATC kodu:

R06AX27

INN (International Adı):

desloratadine

Doz:

0,5mg/ml

Farmasötik formu:

syrup

Paketteki üniteler:

glass bottle 60ml and measuring spoon

Reçete türü:

Prescription

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2019-11-27

Ürün özellikleri

Page 1 of 6
Summary of Product Characteristics
Aerius
®
syrup
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Aerius 0,5 mg/ml syrup
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of syrup contains 0,5 mg of desloratadine.
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Syrup
4.
CLINICAL PARTICULARS
4.1
Therapeutic Indications
For relief of symptoms associated with allergic rhinitis (inflammation
of the nasal
passages caused by an allergy, for example, hay fever or allergy to
dust mites) in
adults, adolescents and children 1 year of age and older. These
symptoms include
sneezing, runny or itchy nose, itchy palate, and itchy, red or watery
eyes.
The product is also used to relieve the symptoms associated with
urticaria (a skin
condition caused by an allergy). These symptoms include itching and
hives.
Relief of these symptoms lasts a full day and helps to resume normal
daily
activities and sleep.
4.2
Posology and Method of Administration
Aerius
®
syrup is taken with or without meal at the following doses:
Pediatric patients:
- Children 1 to 5 years of age: 2.5 ml syrup (1.25 mg desloratadine)
once daily;
- Children 6 to 11 years of age: 5.0 ml syrup (2.5 mg desloratadine)
once daily;
Adults and adolescents (

12years of age): 10.0 ml syrup (5.0 mg desloratadine)
once daily. Intermittent allergic rhinitis (presence of symptoms for
less than 4 days
per week or for less than 4 weeks) should be managed in accordance
with the
evaluation of patient's disease history and the treatment should be
discontinued
after symptoms are resolved and reinitiated upon their reappearance.
In persistent
allergic rhinitis (presence of symptoms for 4 days or more per week
and for more
than 4 weeks), continued treatment may be proposed to the patients
during the
allergen exposure periods.
If you forget to take your dose on time, take it as soon as possible
and then go
back to your regular dosing schedule. Do not take a double dose to
make up for a
forgotten dose.
The safety and efficacy o